Search results
Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?
Investor's Business Daily· 4 months agoMerck stock is shrugging off seven months of underperformance, shooting more than 7% higher in the...
Merck profit tops Wall Street view on strong Keytruda sales
Reuters via Yahoo Finance· 2 years ago(Reuters) -Merck & Co on Thursday reported higher-than-expected second-quarter earnings and revenue...
Merck Scores Major Drug Approval, Easing Pain From Keytruda Patent Expiration
Barrons.com· 1 month agoMerck secured Food and Drug Administration approval for a drug widely expected to be an era-defining...
Pharma CEOs, pressed by Senate panel, refuse to commit to price cuts
BioPharma Dive via Yahoo Finance· 3 months agoThe CEOs of three major drugmakers defended the prices they charge U.S. patients in a Senate...
Merck scraps third prostate cancer study as Keytruda therapy disappoints
Reuters via Yahoo News· 1 year agoMerck & Co on Tuesday scrapped a late-stage trial of a combination therapy with its cancer drug...
Moderna-Merck Partnered Cancer Vaccine Meets Primary Efficacy Endpoint, Stock Jumps
Benzinga via Yahoo Finance· 1 year agoModerna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced the Phase 2b...
Merck (MRK) Beats on Q3 Earnings & Revenues, Ups 2022 View
Zacks via Yahoo Finance· 2 years agoMerck & Co., Inc. MRK reported third-quarter 2022 adjusted earnings of $1.85 per share, beating the...
Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales
Zacks via Yahoo Finance· 6 months agoMerck MRK reported adjusted earnings of $2.13 per share for third-quarter 2023, beating the Zacks...
The Zacks Analyst Blog Highlights Pfizer, Merck and AstraZeneca
Zacks via Yahoo Finance· 7 months agoFor Immediate Release Chicago, IL – September 25, 2023 – Zacks.com announces the list of stocks...
Personalized cancer vaccine results are a 'home run': Moderna CEO
Yahoo Finance via AOL· 1 year agoPreliminary results from a personalized cancer vaccine jointly studied by Moderna (MRNA) and Merck...